COMMUNIQUÉS West-GlobeNewswire

Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025
23/10/2025
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for [...]
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
23/10/2025
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or “Company”), a publicly-trading technology company majority owned by Faraday Future, today announced a [...]
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
23/10/2025
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 [...]
Teladoc Health Announces Chief Financial Officer Transition
23/10/2025
Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual [...]
Treace to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
23/10/2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today [...]
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
23/10/2025
Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ: PTHL) (the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related [...]
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
23/10/2025
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
AVAVA Earns New FDA Clearance for the Treatment of Wrinkles
23/10/2025
The High-Energy Non-Ablative Platform Redefining What’s Possible in Skin Revitalization WALTHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- AVAVA, the powerful non-ablative energy platform powered by Focal Point [...]
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
23/10/2025
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. ( [...]
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
23/10/2025
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
23/10/2025
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, [...]
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
23/10/2025
Following its viral global premiere, ICAN and Del Bigtree release a response to media criticisms of the unpublished vaccinated-versus-unvaccinated study featured in the film AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE [...]
New Clinical Data Confirms Yomi® Robotic System Enhances Efficiency in Dental Implant Surgery
23/10/2025
MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Neocis ® , the leader in robotic-assisted dental surgery, today announced new clinical data highlighting the significant efficiency benefits of its Yomi ® Robotic System, the [...]
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third [...]
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
23/10/2025
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly [...]
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
23/10/2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern [...]
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
23/10/2025
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently [...]

Pages